0001757898-20-000028 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information Document - shares	6 Months Ended
Document and Entity Information Document - shares	Sep. 30, 2020	Oct. 30, 2020
Entity Information [Line Items]
Entity Registrant Name	STERIS plc
Entity Central Index Key	0001757898
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		85,324,006
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-38848
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1455064
Local Phone Number	1 232 2000
City Area Code	353
Document Transition Report	false
Document Quarterly Report	true
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 R296
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Trading Symbol	STE
Security Exchange Name	NYSE
Entity Shell Company	false

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 312,028	$ 319,581
Accounts receivable (net of allowances of $10,276 and $12,051 respectively)	503,724	586,481
Inventories, net	278,593	248,259
Prepaid expenses and other current assets	55,965	54,430
Total current assets	1,150,310	1,208,751
Property, plant, and equipment, net	1,176,066	1,111,855
Other assets	55,172	51,581
Total assets	5,492,567	5,425,582
Current liabilities:
Accounts payable	124,944	149,341
Accrued income taxes	15,831	14,013
Accrued payroll and other related liabilities	114,781	128,261
Accrued expenses and other	158,891	192,183
Total current liabilities	435,418	503,607
Long-term indebtedness	1,020,554	1,150,521
Other Liabilities, Noncurrent	85,076	90,346
Total liabilities	1,830,112	2,018,858
Commitments and contingencies (see Note 8)
Common shares, with $0.001 par value; 500,000 authorized; 85,251 shares issued; and 84,924 shares outstanding	1,990,880	1,982,164
Retained earnings	1,786,878	1,647,175
Accumulated other comprehensive income	(130,613)	(235,463)
Total shareholders' equity	3,647,145	3,393,876
Noncontrolling interest	15,310	12,848
Total equity	3,662,455	3,406,724
Total liabilities and equity	5,492,567	5,425,582
Operating Lease, Right-of-Use Asset	143,041	131,837
Goodwill	2,417,956	2,356,085
Intangible Assets, Net (Excluding Goodwill)	550,022	565,473
Capital Lease Obligations, Current	20,971	19,809
Capital Lease Obligations, Noncurrent	$ 124,337	$ 114,114

CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Mar. 31, 2020
Capital Lease Obligations, Noncurrent	$ 124,337	$ 114,114
Capital Lease Obligations, Current	20,971	19,809
Operating Lease, Right-of-Use Asset	143,041	131,837
Goodwill	2,417,956	2,356,085
Allowance for Doubtful Accounts Receivable, Current	$ 10,276	$ 12,051
Preferred Stock, Shares Authorized	50,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	85,251,000	84,924,000
Common Stock, Shares, Outstanding	85,251,000	84,924,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Intangible Assets, Net (Excluding Goodwill)	$ 550,022	$ 565,473
Deferred Income Taxes and Other Tax Liabilities, Noncurrent	$ 164,727	$ 160,270

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 756,132	$ 736,840	$ 1,425,064	$ 1,433,643
Cost of revenues:
Total cost of revenues	426,095	418,173	809,459	809,133
Gross Profit	330,037	318,667	615,605	624,510
Operating expenses:
Selling, general, and administrative	172,707	175,959	327,877	354,740
Research and development	16,143	16,249	32,374	31,834
Restructuring Costs	(76)	(274)	90	1,115
Total operating expenses	188,774	191,934	360,341	387,689
Income from operations	141,263	126,733	255,264	236,821
Non-operating expenses, net:
Interest expense	8,665	10,444	18,157	20,889
Interest income and miscellaneous expense	(1,188)	(1,018)	(3,477)	(785)
Total non-operating expenses, net	7,477	9,426	14,680	20,104
Income before income tax expense	133,786	117,307	240,584	216,717
Income tax expense	27,778	22,165	46,452	36,798
Net Income	106,008	95,142	194,132	179,919
Less: Net Income Attributable to Noncontrolling Interest	150	373	84	560
Net income (loss) attributable to shareholders	$ 105,858	$ 94,769	$ 194,048	$ 179,359
Net income per common share [Abstract]
Basic	$ 1.24	$ 1.12	$ 2.28	$ 2.12
Diluted	1.23	1.11	2.26	2.09
Cash dividends declared per common share outstanding	$ 0.40	$ 0.37	$ 0.77	$ 0.71
Product [Member]
Revenues:
Total revenues	$ 339,504	$ 337,666	$ 640,612	$ 645,401
Cost of revenues:
Cost of Goods and Services Sold	175,798	183,600	332,353	344,559
Service [Member]
Revenues:
Total revenues	416,628	399,174	784,452	788,242
Cost of revenues:
Cost of Goods and Services Sold	$ 250,297	$ 234,573	$ 477,106	$ 464,574

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net Income	$ 106,008	$ 95,142	$ 194,132	$ 179,919
Less: Net Income Attributable to Noncontrolling Interest	150	373	84	560
Net income (loss) attributable to shareholders	105,858	94,769	194,048	179,359
Other comprehensive (loss) income
Amortization of pension and postretirement benefits plans costs, (net of taxes of $173,$171,$347 and $341, respectively)	(510)	(506)	(1,020)	(1,011)
Change in cumulative foreign current translation adjustment	78,251	(68,367)	105,870	(64,928)
Total other comprehensive (loss) income	77,741	(68,873)	104,850	(65,939)
Comprehensive income	183,599	25,896	298,898	113,420
Other comprehensive (loss) income (parenthetical)
Amortization of pension and postretirement benefits plans costs, tax	$ 173	$ 171	$ 347	$ 341

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands

6 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Net Income

$ 194,132

$ 179,919

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation, depletion, and amortization

103,372

96,736

Deferred income taxes

1,101

(766)

Share-based compensation

13,901

13,276

(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net

178

Loss on sale of businesses, net

^[1]

2,476

Other items

5,460

939

Changes in operating assets and liabilities, net of effects of acquisitions:

Accounts receivable, net

88,134

54,547

Inventories, net

(25,266)

(26,328)

Other current assets

(355)

2,885

Accounts payable

(27,545)

(19,059)

Accruals and other, net

(57,044)

(44,670)

Net cash provided by operating activities

296,073

260,000

Investing activities:

Purchases of property, plant, equipment, and intangibles, net

(110,746)

(98,168)

Proceeds from the sale of property, plant, equipment, and intangibles

275

206

Proceeds from Divestiture of Businesses, Net of Cash Divested

439

Acquisition of businesses, net of cash acquired

(87,935)

Payments for (Proceeds from) Other Investing Activities

(2,392)

Net cash used in investing activities

(112,863)

(185,458)

Financing activities:

Payments on long-term obligations

(35,000)

Proceeds (Payments) under credit facilities, net

(107,162)

13,240

Deferred financing fees and debt issuance costs

(1,206)

(42)

(452)

Repurchases of ordinary shares

(14,434)

(37,866)

Cash dividends paid to ordinary shareholders

(65,560)

(60,220)

Proceeds from issuance of equity to minority shareholders

2,258

Net cash used in financing activities

(199,319)

(63,529)

Effect of exchange rate changes on cash and cash equivalents

8,556

(6,110)

Cash and cash equivalents at beginning of period

319,581

220,633

Cash and cash equivalents at end of period

312,028

225,536

Proceeds from (Payments for) Other Financing Activities

20,621

22,975

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect

$ (7,553)

$ 4,903

[1]	For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	Noncontrolling Interest [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Common Stock [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,185,798	$ 7,988	$ (159,778)	$ 1,339,024	$ 1,998,564
Shares, Issued					84,517
Net Income (Loss) Attributable to Parent	179,359			179,359
Net Income (Loss) Attributable to Noncontrolling Interest	560	560
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	179,919
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(65,939)		(65,939)
Treasury Stock, Shares, Acquired					279
Payments for Repurchase of Common Stock	37,866			(14,562)	$ 52,428
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					559
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	35,524				$ 35,524
Dividends, Common Stock, Cash	60,220			60,220
Noncontrolling Interest, Change in Redemption Value	$ 429	429
Common Stock, Dividends, Per Share, Cash Paid	$ 0.71
Net Income (Loss) Attributable to Parent	$ 179,359			179,359
Net Income (Loss) Attributable to Noncontrolling Interest	560	560
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	179,919
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(65,939)		(65,939)
Treasury Stock, Shares, Acquired					(279)
Payments for Repurchase of Common Stock	(37,866)			14,562	$ (52,428)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					559
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	35,524				$ 35,524
Dividends, Common Stock, Cash	(60,220)			(60,220)
Noncontrolling Interest, Change in Redemption Value	429	429
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,245,002	8,102	(156,844)	1,397,390	$ 1,996,354
Shares, Issued					84,754
Net Income (Loss) Attributable to Parent	94,769			94,769
Net Income (Loss) Attributable to Noncontrolling Interest	373	373
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	95,142
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(68,873)		(68,873)
Treasury Stock, Shares, Acquired					152
Payments for Repurchase of Common Stock	22,981			(11,963)	$ 34,944
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					195
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	20,250				$ 20,250
Dividends, Common Stock, Cash	31,397			31,397
Noncontrolling Interest, Change in Redemption Value	$ 502	502
Common Stock, Dividends, Per Share, Cash Paid	$ 0.37
Net Income (Loss) Attributable to Parent	$ 94,769			94,769
Net Income (Loss) Attributable to Noncontrolling Interest	373	373
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	95,142
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(68,873)		(68,873)
Treasury Stock, Shares, Acquired					(152)
Payments for Repurchase of Common Stock	(22,981)			11,963	$ (34,944)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					195
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	20,250				$ 20,250
Dividends, Common Stock, Cash	(31,397)			(31,397)
Noncontrolling Interest, Change in Redemption Value	502	502
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,237,645
Stockholders' Equity Attributable to Parent			(225,717)	1,472,725	$ 1,981,660
Noncontrolling interest		8,977
Shares, Issued					84,797
Stockholders' Equity Attributable to Parent			(225,717)	1,472,725	$ 1,981,660
Stockholders' Equity Attributable to Noncontrolling Interest		8,977
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,406,724	12,848	(235,463)	1,647,175	$ 1,982,164
Stockholders' Equity Attributable to Parent	3,393,876
Noncontrolling interest	12,848
Shares, Issued					84,924
Stockholders' Equity Attributable to Parent	3,393,876
Stockholders' Equity Attributable to Noncontrolling Interest	12,848
Net Income (Loss) Attributable to Parent	194,048			194,048
Net Income (Loss) Attributable to Noncontrolling Interest	84	84
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	194,132
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	104,850		104,850
Treasury Stock, Shares, Acquired					111
Payments for Repurchase of Common Stock	14,434			(11,215)	$ 25,649
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					438
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	34,365				$ 34,365
Dividends, Common Stock, Cash	65,560			65,560
Noncontrolling Interest, Change in Redemption Value	120	120
Contributions from noncontrolling interest	$ 2,258	(2,258)
Common Stock, Dividends, Per Share, Cash Paid	$ 0.77
Net Income (Loss) Attributable to Parent	$ 194,048			194,048
Net Income (Loss) Attributable to Noncontrolling Interest	84	84
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	194,132
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	104,850		104,850
Treasury Stock, Shares, Acquired					(111)
Payments for Repurchase of Common Stock	(14,434)			11,215	$ (25,649)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					438
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	34,365				$ 34,365
Dividends, Common Stock, Cash	(65,560)			(65,560)
Noncontrolling Interest, Change in Redemption Value	120	120
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,489,713	15,049	(208,354)	1,699,971	$ 1,983,047
Shares, Issued					85,060
Net Income (Loss) Attributable to Parent	105,858			105,858
Net Income (Loss) Attributable to Noncontrolling Interest	150	150
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	106,008
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	77,741		77,741
Treasury Stock, Shares, Acquired					13
Payments for Repurchase of Common Stock	138			(15,138)	$ 15,276
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					204
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	23,109				$ 23,109
Dividends, Common Stock, Cash	34,089			34,089
Noncontrolling Interest, Change in Redemption Value	$ 111	111
Common Stock, Dividends, Per Share, Cash Paid	$ 0.40
Net Income (Loss) Attributable to Parent	$ 105,858			105,858
Net Income (Loss) Attributable to Noncontrolling Interest	150	150
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	106,008
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	77,741		77,741
Treasury Stock, Shares, Acquired					(13)
Payments for Repurchase of Common Stock	(138)			15,138	$ (15,276)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					204
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	23,109				$ 23,109
Dividends, Common Stock, Cash	(34,089)			(34,089)
Noncontrolling Interest, Change in Redemption Value	111	111
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,662,455
Stockholders' Equity Attributable to Parent	3,647,145		(130,613)	1,786,878	$ 1,990,880
Noncontrolling interest	15,310	15,310
Shares, Issued					85,251
Stockholders' Equity Attributable to Parent	3,647,145		$ (130,613)	$ 1,786,878	$ 1,990,880
Stockholders' Equity Attributable to Noncontrolling Interest	$ 15,310	$ 15,310

Nature of Operations and Summary of Significant Accounting Policies(Notes)

6 Months Ended

Sep. 30, 2020

Notes To Financial Statements [Abstract]

Significant Accounting Policies

Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

STERIS plc is a leading provider of infection prevention and other procedural products and services. Our MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration.

Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:

Interim Financial Statements

We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.

These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. The Consolidated Balance Sheet at March 31, 2020 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

Principles of Consolidation

We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.

Use of Estimates

We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and six month periods ended September 30, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.

Revenue Recognition and Associated Liabilities

We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these

contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter.

Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.

We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.

In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.

Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.

We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.

Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At September 30, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.

Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue.

Product Revenue

Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.

Service Revenue

Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair.

We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure.

Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.

Contract Liabilities

Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first six months of fiscal 2021, $36,768 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first six months of fiscal 2020, $42,923 of the March 31, 2019 deferred revenue balance was recorded as revenue.

Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.

Service Liabilities

Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract.

Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.

Remaining Performance Obligations

Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of September 30, 2020, the transaction price allocated to remaining performance obligations was approximately $971,000. We expect to recognize approximately 49% of the transaction price within one year and approximately 45% beyond one year. The remainder has yet to be scheduled for delivery.

Recently Issued Accounting Standards Impacting the Company

Recently Issued Accounting Standards Impacting the Company are presented in the following table:

Standard

Date of Issuance

Description

Date of Adoption

Effect on the financial statements or other significant matters

Standards that have been adopted in fiscal 2021

ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"

June 2016

The standard required a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard was effective for annual periods beginning after December 15, 2019.

First Quarter Fiscal 2021

We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements.

ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement”

August 2018

The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.

First Quarter Fiscal 2021

We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.

ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans"

August 2018

The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans. The standard also clarified disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation. The standard was effective for fiscal years ending after December 15, 2019.

First Quarter Fiscal 2021

We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.

ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract"

August 2018

The standard aligned the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or
obtain internal-use software. The standard was effective for fiscal years beginning after December 15, 2019.

First Quarter Fiscal 2021

We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.

Standards that have not yet been adopted

ASU 2019-12 "Income Taxes (Topic 740)"

December 2019

The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted.

N/A

We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2020.

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)	6 Months Ended
	Sep. 30, 2020
Business Acquisitions and Divestitures [Abstract]
Business Combination Disclosure	Business Acquisitions and Divestitures During the first six months of fiscal 2020, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare and Applied Sterilization Technologies segments. The aggregate purchase price associated with these transactions was approximately $88,829, net of cash acquired and including deferred consideration of $894. Acquisition related costs are reported in the selling, general, and administrative expense line of the Consolidated Statements of Income and amounts are not material. The purchase price for the acquisitions was financed with both cash on hand and with credit facility borrowings. Purchase price allocations are finalized within a measurement period not to exceed one year from closing. Any provisional adjustments recorded were not material. During the first quarter of fiscal 2020, we sold the operations of our Healthcare Specialty Services business that were located in China. We recorded proceeds of $439, net of cash divested, and recognized a pre-tax loss on the sale of $2,330 in the selling, general and administrative expense line of the Consolidated Statements of Income. The business generated annual revenues of approximately $5,000.

Inventories, Net (Notes)

6 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Inventories, Net

We use the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods to value inventory. Inventory valued using the LIFO cost method is stated at the lower of cost or market. Inventory valued using the FIFO cost method is stated at the lower of cost or net realizable value. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:


	September 30, 2020		March 31, 2020
Raw materials	$	101,608	$	94,321
Work in process	40,617		35,643
Finished goods	172,483		151,381
LIFO reserve	(18,752)		(16,937)
Reserve for excess and obsolete inventory	(17,363)		(16,149)
Inventories, net	$	278,593	$	248,259

Property, Plant and Equipment (Notes)

6 Months Ended

Sep. 30, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:


	September 30, 2020		March 31, 2020
Land and land improvements (1)	$	67,407	$	65,994
Buildings and leasehold improvements	546,273		531,267
Machinery and equipment	722,017		682,488
Information systems	182,104		181,112
Radioisotope	547,395		508,593
Construction in progress (1)	196,016		159,731
Total property, plant, and equipment	2,261,212		2,129,185
Less: accumulated depreciation and depletion	(1,085,146)		(1,017,330)
Property, plant, and equipment, net	$	1,176,066	$	1,111,855

(1)Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Notes)

6 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt

Indebtedness was as follows:


	September 30, 2020		March 31, 2020
Credit Agreement	$	170,280	$	275,449
Private Placement	853,310		878,409
Deferred financing costs	(3,036)		(3,337)
Total long term debt	$	1,020,554	$	1,150,521

Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.

Additional Consolidated Balance Sheets Information (Notes)

6 Months Ended

Sep. 30, 2020

Notes To Financial Statements [Abstract]

Additional Consolidated Balance Sheets Information

Additional Consolidated Balance Sheet Information

Additional information related to our Consolidated Balance Sheets is as follows:


	September 30, 2020		March 31, 2020
Accrued payroll and other related liabilities:
Compensation and related items	$	50,424	$	42,205
Accrued vacation/paid time off	14,227		9,917
Accrued bonuses	34,307		53,041
Accrued employee commissions	12,012		19,298

Other postretirement benefit obligations-current portion	1,488		1,488
Other employee benefit plans obligations-current portion	2,323		2,312
Total accrued payroll and other related liabilities	$	114,781	$	128,261
Accrued expenses and other:
Deferred revenues	$	35,035	$	53,299
Service liabilities	39,840		47,505
Self-insured risk reserves-current portion	7,773		7,342
Accrued dealer commissions	20,913		15,827
Accrued warranty	6,951		7,381
Asset retirement obligation-current portion	1,184		2,671
Other	47,195		58,158
Total accrued expenses and other	$	158,891	$	192,183
Other liabilities:
Self-insured risk reserves-long-term portion	$	17,452	$	17,452
Other postretirement benefit obligations-long-term portion	8,861		9,880
Defined benefit pension plans obligations-long-term portion	10,760		10,987
Other employee benefit plans obligations-long-term portion	2,266		2,333
Accrued long-term income taxes	10,841		11,959
Asset retirement obligation-long-term portion	11,560		9,843
Other	23,336		27,892
Total other liabilities	$	85,076	$	90,346

Income Tax Expense (Notes)	6 Months Ended
Income Tax Expense (Notes)	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Expense	Income Tax Expense The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The TCJA reduced the U.S. federal corporate income tax rate to 21.0%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cut and Jobs Act when accounting for the enactment-date effects of the TCJA. We consider the tax expense recorded for the TCJA to be complete at this time. However, it is possible that additional legislation, regulations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments. The effective income tax rates for the three month periods ended September 30, 2020 and 2019 were 20.8% and 18.9%, respectively. The effective income tax rates for the six month periods ended September 30, 2020 and 2019 were 19.3% and 17.0%, respectively. The fiscal 2021 effective tax rate increased when compared to fiscal 2020 primarily due to an increased percentage of profits earned and taxed in jurisdictions with a higher tax rate. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2015. We remain subject to tax authority audits in various jurisdictions wherever we do business. In May 2019, we received two notices of proposed tax adjustment from the U.S. Internal Revenue Service (the “IRS”) regarding the deductibility of interest paid on certain intercompany debt. The notices relate to fiscal years 2016 and 2017. In September 2019, we received another notice of proposed adjustment for the same issue, for the 2018 fiscal year. The IRS adjustments would result in a cumulative tax liability of approximately $40,000. Notices have not been received for subsequent periods. We are contesting the IRS’s assertions, and are scheduled for an initial appeals proceeding later in the 2021 fiscal year. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Contingencies (Notes)	6 Months Ended
Contingencies (Notes)	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020: Item 1 titled “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factors” in Item 1A titled "Product related regulations and claims". From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.

Business Segment Information (Notes)

6 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Business Segment Information

We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.

Prior to April 1, 2020, we operated and reported our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products and Healthcare Specialty Services segments were combined and are now reported as one segment, simply called Healthcare, consistent with the way management now operates and views the business. Prior periods have been recast in the financial tables below for comparability.

Our Healthcare segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. The segment also provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs.

Our Applied Sterilization Technologies ("AST") segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers.

Our Life Sciences segment designs, manufactures and sells consumable products, equipment maintenance, specialty services and capital equipment primarily to pharmaceutical manufacturers around the world.

We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.

For the three and six months ended September 30, 2020, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.

Financial information for each of our segments is presented in the following table:


	Three Months Ended September 30,				Six Months Ended September 30,
	2020		2019		2020		2019
Revenues:
Healthcare	$	470,927	$	485,283	$	870,585	$	931,015
Applied Sterilization Technologies	169,547		152,907		321,909		307,193
Life Sciences	115,658		98,650		232,570		195,435
Total revenues	$	756,132	$	736,840	$	1,425,064	$	1,433,643
Operating income (loss):
Healthcare	$	104,796	$	103,035	$	187,153	$	193,550
Applied Sterilization Technologies	76,835		65,386		140,790		133,421
Life Sciences	46,433		32,315		94,894		65,354
Corporate	(58,155)		(50,956)		(110,522)		(106,353)
Total operating income before adjustments	$	169,909	$	149,780	$	312,315	$	285,972
Less: Adjustments
Amortization of acquired intangible assets (1)	$	21,955	$	18,952	$	39,455	$	35,901
Acquisition and integration related charges (2)	1,135		1,947		2,421		3,864
Redomiciliation and tax restructuring costs (3)	384		1,016		554		2,786

Net (gain) loss on divestiture of businesses (1)	(5)		50		5		2,476
Amortization of property "step up" to fair value (1)	714		446		1,317		1,181
COVID-19 incremental costs (4)	4,539		—		13,209		—
Restructuring charges (5)	(76)		636		90		2,943
Total operating income	$	141,263	$	126,733	$	255,264	$	236,821

(1) For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.

(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

(3) Costs incurred in connection with the Redomiciliation.

(4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.

(5) For more information regarding our restructuring efforts refer to Note 2 titled, "Restructuring".

Additional information regarding our fiscal 2021 and fiscal 2020 revenue is disclosed in the following tables:


	Three Months Ended September 30,				Six Months Ended September 30,
	2020		2019		2020		2019
Healthcare:
Capital equipment	$	131,673	$	152,631	$	259,755	273,486
Consumables	122,797		116,033		206,551		232,115
Service	216,457		216,619		404,279		425,414
Total Healthcare Revenues	$	470,927	$	485,283	$	870,585	$	931,015
Applied Sterilization Technologies Service Revenues	$	169,547	$	152,907	$	321,909	$	307,193
Life Sciences:
Capital equipment	$	29,241	$	26,462	$	59,671	$	53,231
Consumables	55,793		42,540		114,635		86,569
Service	30,624		29,648		58,264		55,635
Total Life Sciences Revenues	$	115,658	$	98,650	$	232,570	$	195,435
Total Revenues	$	756,132	$	736,840	$	1,425,064	$	1,433,643


	Three Months Ended September 30,				Six Months Ended September 30,
	2020		2019		2020		2019
Revenues:
Ireland	$	17,090	$	15,171	$	31,463	$	30,279
United States	549,449		538,101		1,041,157		1,049,253
Other locations	189,593		183,568		352,444		354,111
Total Revenues	$	756,132	$	736,840	$	1,425,064	$	1,433,643

Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments.

Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.


	September 30, 2020		March 31, 2020
Assets:
Healthcare and Life Sciences	$	2,642,515	$	2,705,377
Applied Sterilization Technologies	2,850,052		2,720,205
Total assets	$	5,492,567	$	5,425,582

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Shares and Preferred Shares (Notes)

6 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Earnings Per Share

Shares and Preferred Shares

Ordinary shares

We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method.

The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:


	Three Months Ended September 30,		Six Months Ended September 30,
Denominator (shares in thousands):	2020	2019	2020	2019
Weighted average shares outstanding—basic	85,170	84,795	85,065	84,716
Dilutive effect of share equivalents	674	900	695	914
Weighted average shares outstanding and share equivalents—diluted	85,844	85,695	85,760	85,630

Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:


	Three Months Ended September 30,		Six Months Ended September 30,
(shares in thousands)	2020	2019	2020	2019
Number of share options	503	341	416	231

Additional Authorized Shares

The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Equity	6 Months Ended
Equity	Sep. 30, 2020
Equity [Abstract]
Treasury Stock	Repurchases of Ordinary Shares On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of September 30, 2020, there was approximately $333,932 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date. Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020. From the start of fiscal 2021 through April 9, 2020, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During the first six months of fiscal 2020, we repurchased 205,059 of our ordinary shares for the aggregate amount of $30,000 (net of fees and commissions) pursuant to the authorizations. During the first six months of fiscal 2021 we obtained 76,286 of our ordinary shares in the aggregate amount of $9,386 in connection with share based compensation award programs. During the first six months of fiscal 2020, we obtained 73,914 of our ordinary shares in the aggregate amount of $7,955 in connection with share based compensation award programs.

Share-Based Compensation (Notes)

6 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Board of Directors or the Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares.

Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of September 30, 2020, 3,568,985 ordinary shares remained available for grant under the long-term incentive plan.

The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits.

The following weighted-average assumptions were used for options granted during the first six months of fiscal 2021 and 2020:


	Fiscal 2021		Fiscal 2020
Risk-free interest rate	0.46	%	2.26	%
Expected life of options	6.0 years		6.2 years
Expected dividend yield of stock	0.96	%	1.22	%
Expected volatility of stock	23.04	%	20.27	%

The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.78% and 2.77% was applied in fiscal 2021 and 2020, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.

A summary of share option activity is as follows:


	Number of Options	Weighted Average Exercise Price Per Share		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2020	1,796,126	$	91.29
Granted	288,936	181.33
Exercised	(292,199)	71.96
Forfeited	(32,002)	121.80

Outstanding at September 30, 2020	1,760,861	$	108.72	7.0 years	$	120,484
Exercisable at September 30, 2020	988,477	$	80.98	5.7 years	$	94,113

We estimate that 749,747 of the non-vested stock options outstanding at September 30, 2020 will ultimately vest.

The aggregate intrinsic value in the table above represents the total pre-tax difference between the $176.19 closing price of our ordinary shares on September 30, 2020 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares.

The total intrinsic value of stock options exercised during the first six months of fiscal 2021 and fiscal 2020 was $25,244 and $35,886, respectively. Net cash proceeds from the exercise of stock options were $20,600 and $22,371 for the first six months of fiscal 2021 and fiscal 2020, respectively.

The weighted average grant date fair value of stock option grants was $27.66 and $23.52 for the first six months of fiscal 2021 and fiscal 2020, respectively.

Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of September 30, 2020 and 2019 was $448 and $587, respectively.

A summary of the non-vested restricted share and share unit activity is presented below:


	Number of Restricted Shares	Number of Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2020	575,830	30,894	$	98.07
Granted	137,385	14,124	164.45
Vested	(156,390)	(16,150)	84.64
Forfeited	(15,430)	—	102.07
Non-vested at September 30, 2020	541,395	28,868	$	119.72

Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first six months of fiscal 2021 at the time of grant was $14,604.

As of September 30, 2020, there was a total of $57,787 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.3 years.

Financial and Other Guarantees(Notes)

6 Months Ended

Sep. 30, 2020

Product Warranties Disclosures [Abstract]

Product Warranty Disclosure

Financial and Other Guarantees

We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

Changes in our warranty liability during the first six months of fiscal 2021 were as follows:


	Warranties
Balance, March 31, 2020	$	7,381
Warranties issued during the period	4,866
Settlements made during the period	(5,296)
Balance, September 30, 2020	$	6,951

Deritvatives and Hedging (Notes)

6 Months Ended

Sep. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure

Derivatives and HedgingFrom time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the second quarter

of fiscal 2021, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2021. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes.

None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At September 30, 2020, we held foreign currency forward contracts to buy 69.9 million Mexican pesos and 4.5 million Canadian dollars; and to sell 8.0 million euros. At September 30, 2020 we held commodity swap contracts to buy 357.6 thousand pounds of nickel.


	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance sheet location	September 30, 2020		March 31, 2020		September 30, 2020		March 31, 2020
Prepaid & Other	$	538	$	124	$	—	$	—
Accrued expenses and other	$	—	$	—	$	609	$	912

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:


	Location of gain (loss) recognized in income	Amount of gain (loss) recognized in income
		Three Months Ended September 30,				Six Months Ended September 30,
		2020		2019		2020		2019
Foreign currency forward contracts	Selling, general and administrative	$	(223)	$	299	$	(80)	$	705
Commodity swap contracts	Cost of revenues	$	386	$	796	$	751	$	669

Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $48,753 at September 30, 2020. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements (Notes)

6 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Disclosures

. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions.

The following table shows the fair value of our financial assets and liabilities at September 30, 2020 and March 31, 2020:


					Fair Value Measurements
	Carrying Value				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
					Level 1				Level 2				Level 3
	September 30,		March 31,		September 30,		March 31,		September 30,		March 31,		September 30,		March 31,
Assets:
Cash and cash equivalents	$	312,028	$	319,581	$	312,028	$	319,581	$	—	$	—	$	—	$	—
Forward and swap contracts (1)	538		124		—		—		538		124		—		—
Equity investments(2)	9,868		9,624		9,868		9,624		—		—		—		—
Other investments	2,654		2,507		2,654		2,507		—		—		—		—

Liabilities:
Forward and swap contracts (1)	$	609	$	912	$	—	$	—	$	609	$	912	$	—	$	—
Deferred compensation plans (2)	1,662		1,475		1,662		1,475		—		—		—		—
Long term debt (3)	1,020,554		1,150,521		—		—		1,081,626		1,143,978		—		—
Contingent consideration obligations (4)	16,364		15,988		—		—		—		—		16,364		15,988

(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.

(2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the second quarter and first half of fiscal 2021, we recorded losses of $384 and $74, respectively, related to these investments. During the second quarter and first half of fiscal 2020, we recorded losses of $721 and $2,479, respectively, related to these investments.

(3) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.

(4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at September 30, 2020 are summarized as follows:


	Contingent Consideration
Balance at March 31, 2020	$	15,988
Additions	538
Payments	(42)

Currency translation adjustments	(120)

Balance at September 30, 2020	$	16,364

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)

6 Months Ended

Sep. 30, 2020

Reclassifications out of AOCI [Abstract]

Comprehensive Income (Loss) Note [Text Block]

Reclassifications Out of Accumulated Other Comprehensive Income (Loss)

Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended September 30, 2020 and 2019 were as follows:


	Defined Benefit Plans (1)				Currency Translation (2)				Total Accumulated Other Comprehensive Income (Loss)
	Three Months		Six Months		Three Months		Six Months		Three Months		Six Months
Beginning Balance	$	(7,323)	$	(6,813)	$	(201,031)	$	(228,650)	$	(208,354)	$	(235,463)
Other Comprehensive Income before reclassifications	324		648		78,251		105,870		78,575		106,518
Amounts reclassified from Accumulated Other Comprehensive (Loss)	(834)		(1,668)		—		—		(834)		(1,668)
Net current-period Other Comprehensive (Loss) Income	(510)		(1,020)		78,251		105,870		77,741		104,850
Balance at September 30, 2020	$	(7,833)	$	(7,833)	$	(122,780)	$	(122,780)	$	(130,613)	$	(130,613)

(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.


	Defined Benefit Plans (1)				Currency Translation (2)				Total Accumulated Other Comprehensive Income (Loss)
	Three Months		Six Months		Three Months		Six Months		Three Months		Six Months
Beginning Balance	$	(4,709)	$	(4,204)	$	(152,135)	$	(155,574)	$	(156,844)	$	(159,778)
Other Comprehensive Income (Loss) before reclassifications	189		379		(68,367)		(64,928)		(68,178)		(64,549)
Amounts reclassified from Accumulated Other Comprehensive (Loss)	(695)		(1,390)		—		—		(695)		(1,390)
Net current-period Other Comprehensive (Loss)	(506)		(1,011)		(68,367)		(64,928)		(68,873)		(65,939)
Balance at September 30, 2019	$	(5,215)	$	(5,215)	$	(220,502)	$	(220,502)	$	(225,717)	$	(225,717)

1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

Loans Receivable (Notes)	6 Months Ended
Loans Receivable (Notes)	Sep. 30, 2020
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Loans Receivable In connection with an equity investment of $4,955, we agreed to provide a credit facility of up to approximately $11,000 for a term of up to seven years ending in 2025. The loan carries an interest rate of 4% compounded daily and payable annually. Outstanding borrowings under the agreement totaled $9,864 at September 30, 2020 and $7,084 at March 31, 2020. In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carried an interest rate of 4% for the first four years and 12% thereafter. The loan was renegotiated during the third quarter of fiscal 2020. According to the new terms of the loan agreement, the outstanding balance at October 31, 2019, of €7,300, will be repaid in six equal annual installments beginning on October 18, 2022. The loan carries an interest rate of 4% for the first four years and 8% thereafter. Outstanding borrowings under the agreement totaled $8,545 (or €7,300) at September 30, 2020 and $8,072 (or €7,300) at March 31, 2020. Amounts for loan receivables as noted above are recorded in the "Other assets" line of our Consolidated balance sheets. Interest income is not material.

Restructuring (Notes)	6 Months Ended
Restructuring (Notes)	Sep. 30, 2020
Restructuring [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency. Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,941 related to these restructuring actions, of which $31,750 was recorded as restructuring expenses and $12,191 was recorded in cost of revenues, with a total of $34,116, $7,474 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,683. Additional restructuring expenses related to this plan are not expected to be material to our results of operations. Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at September 30, 2020 and March 31, 2020 are not material. For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.

Unusual or Infrequently Occurring Items	6 Months Ended
Unusual or Infrequently Occurring Items	Sep. 30, 2020
Unusual or Infrequent Items, or Both [Abstract]
COVID-19 Pandemic	COVID-19 Pandemic The COVID-19 pandemic began to impact our business late in fiscal 2020. The pandemic and related public health recommendations and mandated precautions to mitigate the spread of COVID-19, including deferral of medical procedures and treatments and shelter-in-place orders or similar measures, have negatively affected and are expected to continue to negatively affect some of our operations, which may impact our financial position and cash flows. We have experienced and expect to continue to experience unpredictable fluctuations in demand for certain of our products and services, including some products and services that are experiencing increased demand. To date, we do not believe that the COVID-19 pandemic has had a significant impact on our operations, as we have been able to continue to operate our manufacturing facilities and meet the demand for essential products and services of our Customers. In response to the pandemic, we have implemented several measures that we believe will help us to protect the health and safety of our employees, preserve liquidity and enhance our financial flexibility. For our employees, we allowed employees to work remotely when possible and have implemented additional safety measures in compliance with applicable regulations to allow personnel to continue to work in our facilities. We suspended all non-essential travel and enacted a temporary hiring freeze on certain positions. To manage liquidity, we have suspended our stock repurchase program and deferred certain planned capital expenditures; however, we have continued to invest in expansion projects as planned. We do not believe that these actions will negatively impact our long-term ability to generate revenues or meet existing and future financial obligations. While we have been impacted and expect this situation to continue to have an impact on our business, the full impact to our results of operations and financial position cannot be reasonably estimated at this time. For additional information and our risk factors related to the COVID-19 pandemic, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.

Subsequent Events	6 Months Ended
Subsequent Events	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On October 2, 2020, we entered into a purchase agreement to acquire all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a portfolio company of Water Street Healthcare Partners, LLC and is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical is expected to be integrated into our Healthcare segment. We anticipate that the acquisition will be completed before December 31, 2020. The purchase price is $850,000 in cash, or approximately $810,000 net of tax benefits, and is subject to customary adjustments. We are not assuming any pre-existing debt, and intend to fund the purchase through a combination of debt and cash on hand. On October 2, 2020, we entered into a financing commitment with several lenders providing for the establishment of a new senior unsecured three year term loan credit facility to be effective upon closing of the acquisition in the amount of $550,000 to partially fund the acquisition. As a result of limited access to the information required to prepare the initial accounting, we are unable to provide the amounts that will be recognized at the acquisition date for the major classes of assets acquired and liabilities assumed, pre-existing contingencies, goodwill or other intangible assets at the time of this Form 10-Q filing.

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
Use of Estimates	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and six month periods ended September 30, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.
Revenue	Revenue Recognition and Associated Liabilities We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter. Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At September 30, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first six months of fiscal 2021, $36,768 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first six months of fiscal 2020, $42,923 of the March 31, 2019 deferred revenue balance was recorded as revenue. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of September 30, 2020, the transaction price allocated to remaining performance obligations was approximately $971,000. We expect to recognize approximately 49% of the transaction price within one year and approximately 45% beyond one year. The remainder has yet to be scheduled for delivery

Accounting Policies (Tables)

6 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

New Accounting Pronouncement, Early Adoption

Recently Issued Accounting Standards Impacting the Company are presented in the following table:

Standard

Date of Issuance

Description

Date of Adoption

Effect on the financial statements or other significant matters

Standards that have been adopted in fiscal 2021

ASU 2016-13, "Measurement of Credit Losses on Financial Instruments"

June 2016

First Quarter Fiscal 2021

We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements.

ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement”

August 2018

First Quarter Fiscal 2021

We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.

ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans"

August 2018

First Quarter Fiscal 2021

We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only.

August 2018

First Quarter Fiscal 2021

We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.

Standards that have not yet been adopted

ASU 2019-12 "Income Taxes (Topic 740)"

December 2019

N/A

We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

Inventories, Net Inventories, Net (Tables)

6 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:


	September 30, 2020		March 31, 2020
Raw materials	$	101,608	$	94,321
Work in process	40,617		35,643
Finished goods	172,483		151,381
LIFO reserve	(18,752)		(16,937)
Reserve for excess and obsolete inventory	(17,363)		(16,149)
Inventories, net	$	278,593	$	248,259

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)

6 Months Ended

Sep. 30, 2020

Notes To Financial Statements [Abstract]

Additional Consolidated Balance Sheets Information

Additional Consolidated Balance Sheet Information

Additional information related to our Consolidated Balance Sheets is as follows:


	September 30, 2020		March 31, 2020
Accrued payroll and other related liabilities:
Compensation and related items	$	50,424	$	42,205
Accrued vacation/paid time off	14,227		9,917
Accrued bonuses	34,307		53,041
Accrued employee commissions	12,012		19,298

Other postretirement benefit obligations-current portion	1,488		1,488
Other employee benefit plans obligations-current portion	2,323		2,312
Total accrued payroll and other related liabilities	$	114,781	$	128,261
Accrued expenses and other:
Deferred revenues	$	35,035	$	53,299
Service liabilities	39,840		47,505
Self-insured risk reserves-current portion	7,773		7,342
Accrued dealer commissions	20,913		15,827
Accrued warranty	6,951		7,381
Asset retirement obligation-current portion	1,184		2,671
Other	47,195		58,158
Total accrued expenses and other	$	158,891	$	192,183
Other liabilities:
Self-insured risk reserves-long-term portion	$	17,452	$	17,452
Other postretirement benefit obligations-long-term portion	8,861		9,880
Defined benefit pension plans obligations-long-term portion	10,760		10,987
Other employee benefit plans obligations-long-term portion	2,266		2,333
Accrued long-term income taxes	10,841		11,959
Asset retirement obligation-long-term portion	11,560		9,843
Other	23,336		27,892
Total other liabilities	$	85,076	$	90,346

Schedule of Accrued Liabilities [Table Text Block]

Additional information related to our Consolidated Balance Sheets is as follows:


	September 30, 2020		March 31, 2020
Accrued payroll and other related liabilities:
Compensation and related items	$	50,424	$	42,205
Accrued vacation/paid time off	14,227		9,917
Accrued bonuses	34,307		53,041
Accrued employee commissions	12,012		19,298

Other postretirement benefit obligations-current portion	1,488		1,488
Other employee benefit plans obligations-current portion	2,323		2,312
Total accrued payroll and other related liabilities	$	114,781	$	128,261
Accrued expenses and other:
Deferred revenues	$	35,035	$	53,299
Service liabilities	39,840		47,505
Self-insured risk reserves-current portion	7,773		7,342
Accrued dealer commissions	20,913		15,827
Accrued warranty	6,951		7,381
Asset retirement obligation-current portion	1,184		2,671
Other	47,195		58,158
Total accrued expenses and other	$	158,891	$	192,183
Other liabilities:
Self-insured risk reserves-long-term portion	$	17,452	$	17,452
Other postretirement benefit obligations-long-term portion	8,861		9,880
Defined benefit pension plans obligations-long-term portion	10,760		10,987
Other employee benefit plans obligations-long-term portion	2,266		2,333
Accrued long-term income taxes	10,841		11,959
Asset retirement obligation-long-term portion	11,560		9,843
Other	23,336		27,892
Total other liabilities	$	85,076	$	90,346

Business Segment Information Business Segment Information (Tables)

6 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Financial information for each of our segments is presented in the following table:


	Three Months Ended September 30,				Six Months Ended September 30,
	2020		2019		2020		2019
Revenues:
Healthcare	$	470,927	$	485,283	$	870,585	$	931,015
Applied Sterilization Technologies	169,547		152,907		321,909		307,193
Life Sciences	115,658		98,650		232,570		195,435
Total revenues	$	756,132	$	736,840	$	1,425,064	$	1,433,643
Operating income (loss):
Healthcare	$	104,796	$	103,035	$	187,153	$	193,550
Applied Sterilization Technologies	76,835		65,386		140,790		133,421
Life Sciences	46,433		32,315		94,894		65,354
Corporate	(58,155)		(50,956)		(110,522)		(106,353)
Total operating income before adjustments	$	169,909	$	149,780	$	312,315	$	285,972
Less: Adjustments
Amortization of acquired intangible assets (1)	$	21,955	$	18,952	$	39,455	$	35,901
Acquisition and integration related charges (2)	1,135		1,947		2,421		3,864
Redomiciliation and tax restructuring costs (3)	384		1,016		554		2,786

Net (gain) loss on divestiture of businesses (1)	(5)		50		5		2,476
Amortization of property "step up" to fair value (1)	714		446		1,317		1,181
COVID-19 incremental costs (4)	4,539		—		13,209		—
Restructuring charges (5)	(76)		636		90		2,943
Total operating income	$	141,263	$	126,733	$	255,264	$	236,821

Revenue from External Customers by Products and Services [Table Text Block]


	Three Months Ended September 30,				Six Months Ended September 30,
	2020		2019		2020		2019
Healthcare:
Capital equipment	$	131,673	$	152,631	$	259,755	273,486
Consumables	122,797		116,033		206,551		232,115
Service	216,457		216,619		404,279		425,414
Total Healthcare Revenues	$	470,927	$	485,283	$	870,585	$	931,015
Applied Sterilization Technologies Service Revenues	$	169,547	$	152,907	$	321,909	$	307,193
Life Sciences:
Capital equipment	$	29,241	$	26,462	$	59,671	$	53,231
Consumables	55,793		42,540		114,635		86,569
Service	30,624		29,648		58,264		55,635
Total Life Sciences Revenues	$	115,658	$	98,650	$	232,570	$	195,435
Total Revenues	$	756,132	$	736,840	$	1,425,064	$	1,433,643

Revenue from External Customers by Geographic Areas [Table Text Block]


	Three Months Ended September 30,				Six Months Ended September 30,
	2020		2019		2020		2019
Revenues:
Ireland	$	17,090	$	15,171	$	31,463	$	30,279
United States	549,449		538,101		1,041,157		1,049,253
Other locations	189,593		183,568		352,444		354,111
Total Revenues	$	756,132	$	736,840	$	1,425,064	$	1,433,643

Reconciliation of Assets from Segment to Consolidated


	September 30, 2020		March 31, 2020
Assets:
Healthcare and Life Sciences	$	2,642,515	$	2,705,377
Applied Sterilization Technologies	2,850,052		2,720,205
Total assets	$	5,492,567	$	5,425,582

Shares and Preferred Shares Shares and Preferred Shares (Tables)

6 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Schedule of Weighted Average Number of Shares [Table Text Block]


	Three Months Ended September 30,		Six Months Ended September 30,
Denominator (shares in thousands):	2020	2019	2020	2019
Weighted average shares outstanding—basic	85,170	84,795	85,065	84,716
Dilutive effect of share equivalents	674	900	695	914
Weighted average shares outstanding and share equivalents—diluted	85,844	85,695	85,760	85,630

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]


	Three Months Ended September 30,		Six Months Ended September 30,
(shares in thousands)	2020	2019	2020	2019
Number of share options	503	341	416	231

Share-Based Compensation Share-Based Compensation (Tables)

6 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Assumptions Used

The following weighted-average assumptions were used for options granted during the first six months of fiscal 2021 and 2020:


	Fiscal 2021		Fiscal 2020
Risk-free interest rate	0.46	%	2.26	%
Expected life of options	6.0 years		6.2 years
Expected dividend yield of stock	0.96	%	1.22	%
Expected volatility of stock	23.04	%	20.27	%

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding

A summary of share option activity is as follows:


	Number of Options	Weighted Average Exercise Price Per Share		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2020	1,796,126	$	91.29
Granted	288,936	181.33
Exercised	(292,199)	71.96
Forfeited	(32,002)	121.80

Outstanding at September 30, 2020	1,760,861	$	108.72	7.0 years	$	120,484
Exercisable at September 30, 2020	988,477	$	80.98	5.7 years	$	94,113

Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest

A summary of the non-vested restricted share and share unit activity is presented below:


	Number of Restricted Shares	Number of Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2020	575,830	30,894	$	98.07
Granted	137,385	14,124	164.45
Vested	(156,390)	(16,150)	84.64
Forfeited	(15,430)	—	102.07
Non-vested at September 30, 2020	541,395	28,868	$	119.72

Financial and Other Guarantees Financial and Other Gurantees (Tables)

6 Months Ended

Sep. 30, 2020

Product Warranties Disclosures [Abstract]

Schedule of Product Warranty Liability

Changes in our warranty liability during the first six months of fiscal 2021 were as follows:


	Warranties
Balance, March 31, 2020	$	7,381
Warranties issued during the period	4,866
Settlements made during the period	(5,296)
Balance, September 30, 2020	$	6,951

Derivatives and Hedging Derivatives and Hedging (Tables)

6 Months Ended

Sep. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value


	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance sheet location	September 30, 2020		March 31, 2020		September 30, 2020		March 31, 2020
Prepaid & Other	$	538	$	124	$	—	$	—
Accrued expenses and other	$	—	$	—	$	609	$	912

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:


	Location of gain (loss) recognized in income	Amount of gain (loss) recognized in income
		Three Months Ended September 30,				Six Months Ended September 30,
		2020		2019		2020		2019
Foreign currency forward contracts	Selling, general and administrative	$	(223)	$	299	$	(80)	$	705
Commodity swap contracts	Cost of revenues	$	386	$	796	$	751	$	669

Fair Value Measurements Fair Value Measurements (Tables)

6 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at September 30, 2020 are summarized as follows:


	Contingent Consideration
Balance at March 31, 2020	$	15,988
Additions	538
Payments	(42)

Currency translation adjustments	(120)

Balance at September 30, 2020	$	16,364

Fair Value Option, Disclosures

The following table shows the fair value of our financial assets and liabilities at September 30, 2020 and March 31, 2020:


					Fair Value Measurements
	Carrying Value				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
					Level 1				Level 2				Level 3
	September 30,		March 31,		September 30,		March 31,		September 30,		March 31,		September 30,		March 31,
Assets:
Cash and cash equivalents	$	312,028	$	319,581	$	312,028	$	319,581	$	—	$	—	$	—	$	—
Forward and swap contracts (1)	538		124		—		—		538		124		—		—
Equity investments(2)	9,868		9,624		9,868		9,624		—		—		—		—
Other investments	2,654		2,507		2,654		2,507		—		—		—		—

Liabilities:
Forward and swap contracts (1)	$	609	$	912	$	—	$	—	$	609	$	912	$	—	$	—
Deferred compensation plans (2)	1,662		1,475		1,662		1,475		—		—		—		—
Long term debt (3)	1,020,554		1,150,521		—		—		1,081,626		1,143,978		—		—
Contingent consideration obligations (4)	16,364		15,988		—		—		—		—		16,364		15,988

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)

6 Months Ended

Sep. 30, 2020

Reclassifications out of AOCI [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended September 30, 2020 and 2019 were as follows:


	Defined Benefit Plans (1)				Currency Translation (2)				Total Accumulated Other Comprehensive Income (Loss)
	Three Months		Six Months		Three Months		Six Months		Three Months		Six Months
Beginning Balance	$	(7,323)	$	(6,813)	$	(201,031)	$	(228,650)	$	(208,354)	$	(235,463)
Other Comprehensive Income before reclassifications	324		648		78,251		105,870		78,575		106,518
Amounts reclassified from Accumulated Other Comprehensive (Loss)	(834)		(1,668)		—		—		(834)		(1,668)
Net current-period Other Comprehensive (Loss) Income	(510)		(1,020)		78,251		105,870		77,741		104,850
Balance at September 30, 2020	$	(7,833)	$	(7,833)	$	(122,780)	$	(122,780)	$	(130,613)	$	(130,613)

(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.


	Defined Benefit Plans (1)				Currency Translation (2)				Total Accumulated Other Comprehensive Income (Loss)
	Three Months		Six Months		Three Months		Six Months		Three Months		Six Months
Beginning Balance	$	(4,709)	$	(4,204)	$	(152,135)	$	(155,574)	$	(156,844)	$	(159,778)
Other Comprehensive Income (Loss) before reclassifications	189		379		(68,367)		(64,928)		(68,178)		(64,549)
Amounts reclassified from Accumulated Other Comprehensive (Loss)	(695)		(1,390)		—		—		(695)		(1,390)
Net current-period Other Comprehensive (Loss)	(506)		(1,011)		(68,367)		(64,928)		(68,873)		(65,939)
Balance at September 30, 2019	$	(5,215)	$	(5,215)	$	(220,502)	$	(220,502)	$	(225,717)	$	(225,717)

1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

Restructuring (Tables)	6 Months Ended
Restructuring (Tables)	Sep. 30, 2020
Restructuring [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency. Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,941 related to these restructuring actions, of which $31,750 was recorded as restructuring expenses and $12,191 was recorded in cost of revenues, with a total of $34,116, $7,474 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,683. Additional restructuring expenses related to this plan are not expected to be material to our results of operations. Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at September 30, 2020 and March 31, 2020 are not material. For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.

Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Revenue, Remaining Performance Obligation, Amount		$ 971,000
Deferred Revenues, Amount recognized in period from certain capital contracts	$ 14,609
Deferred Cost of Revenues, Amount recognized in period from certain capital contracts	$ 7,560
Deferred Revenue, Revenue Recognized		$ 36,768	$ 42,923
Expected recognition within the next year [Member]
Revenue, Remaining Performance Obligation, Percentage		45.00%
Expected recognition beyond the next year [Member] [Member]
Revenue, Remaining Performance Obligation, Percentage		49.00%

Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Mar. 31, 2020

Business Acquisition [Line Items]

Contingent consideration

$ 16,364

$ 15,988

Deferred consideration

$ 894

Proceeds from Sales of Business, Affiliate and Productive Assets

439

Gain (Loss) on Disposition of Business

^[1]

$ 5

(50)

$ (5)

(2,476)

Approximate annual revenues of divested entity

5,000

Series of Individually Immaterial Business Acquisitions

Business Acquisition [Line Items]

Approximate purchase price of entity

$ 88,829

[1]	For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.

Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Mar. 31, 2020
Business Acquisition [Line Items]
Revenues	$ 756,132	$ 736,840	$ 1,425,064	$ 1,433,643
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 2,417,956		$ 2,417,956		$ 2,356,085

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Revenues

$ 756,132

$ 736,840

$ 1,425,064

$ 1,433,643

Pre-tax gain or loss on sale of business

^[1]

$ (5)

$ 50

$ 5

$ 2,476

[1]	For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.

- Definition

+ References

+ Details

Business Acquisitions and Divestitures Revenues by Type (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2019 USD ($)
Business Combinations [Abstract]
Loss on sale of HSS China Operations	$ 2,330

Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Mar. 31, 2020
Raw materials	$ 101,608	$ 94,321
Work in process	40,617	35,643
Finished goods	172,483	151,381
LIFO reserve	(18,752)	(16,937)
Reserve for excess and obsolete inventory	(17,363)	(16,149)
Inventories, net	$ 278,593	$ 248,259

Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($)
$ in Thousands

6 Months Ended

Sep. 30, 2020

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:


	September 30, 2020		March 31, 2020
Land and land improvements (1)	$	67,407	$	65,994
Buildings and leasehold improvements	546,273		531,267
Machinery and equipment	722,017		682,488
Information systems	182,104		181,112
Radioisotope	547,395		508,593
Construction in progress (1)	196,016		159,731
Total property, plant, and equipment	2,261,212		2,129,185
Less: accumulated depreciation and depletion	(1,085,146)		(1,017,330)
Property, plant, and equipment, net	$	1,176,066	$	1,111,855

(1)Land is not depreciated. Construction in progress is not depreciated until placed in service.

Property, Plant and Equipment [Line Items]

Land and land improvements

^[1]

$ 67,407

$ 65,994

Buildings and leasehold improvements

546,273

531,267

Machinery and equipment

722,017

682,488

Radioisotope

547,395

508,593

Construction in progress

^[1]

196,016

159,731

Total property, plant, and equipment

2,261,212

2,129,185

Less: accumulated depreciation and depletion

(1,085,146)

(1,017,330)

Property, plant, and equipment, net

1,176,066

1,111,855

Capitalized Computer Hardware/Software, Gross

$ 182,104

$ 181,112

[1]	Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Details) - USD ($)
$ in Thousands

6 Months Ended

Sep. 30, 2020

Mar. 31, 2020

Debt Disclosure [Abstract]

Schedule of Debt

Indebtedness was as follows:


	September 30, 2020		March 31, 2020
Credit Agreement	$	170,280	$	275,449
Private Placement	853,310		878,409
Deferred financing costs	(3,036)		(3,337)
Total long term debt	$	1,020,554	$	1,150,521

Debt Instrument [Line Items]

Private Placement

$ 853,310

$ 878,409

Deferred financing costs

3,036

3,337

Credit Agreement

170,280

275,449

Total long term debt

$ 1,020,554

$ 1,150,521

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Mar. 31, 2020
Accrued payroll and other related liabilities:
Compensation and related items	$ 50,424	$ 42,205
Accrued vacation/paid time off	14,227	9,917
Accrued bonuses	34,307	53,041
Accrued employee commissions	12,012	19,298
Other postretirement benefit obligations-current portion	1,488	1,488
Other employee benefit plans obligations-current portion	2,323	2,312
Accrued expenses and other:
Deferred revenues	35,035	53,299
Service liabilities	39,840	47,505
Self-insured risk reserves-current portion	7,773	7,342
Accrued dealer commissions	20,913	15,827
Accrued warranty	6,951	7,381
Asset retirement obligation-current portion	1,184	2,671
Other	47,195	58,158
Total accrued expenses and other	158,891	192,183
Other liabilities:
Self-insured risk reserves-long-term portion	17,452	17,452
Other postretirement benefit obligations-long-term portion	8,861	9,880
Defined benefit pension plans obligations-long-term portion	10,760	10,987
Other employee benefit plans obligations-long-term portion	2,266	2,333
Accrued long-term income taxes	10,841	11,959
Asset retirement obligation-long-term portion	11,560	9,843
Long-term liabilities, other	23,336	27,892
Other Liabilities, Noncurrent	85,076	90,346
Employee-related Liabilities, Current	$ 114,781	$ 128,261

Income Tax Expense Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective Income Tax Rate, Continuing Operations	20.80%	18.90%	19.30%	17.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%
Uncertain Tax Liability Resulting From IRS Notice	$ 40,000		$ 40,000

Business Segment Information Business Segment Information (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Mar. 31, 2020

Segment Reporting Information [Line Items]

Revenues

$ 756,132

$ 736,840

$ 1,425,064

$ 1,433,643

Segment operating income

141,263

126,733

255,264

236,821

Restructuring Charges

^[1]

(76)

636

2,943

Amortization of acquired intangible assets

^[2]

21,955

18,952

39,455

35,901

Business Combination, Acquisition Related Costs

^[3]

1,135

1,947

2,421

3,864

Impact of TCJA

^[4]

384

1,016

554

2,786

Net loss on divestiture of businesses

^[2]

(5)

2,476

Amortization of inventory and property step-up to fair value

^[2]

714

446

1,317

1,181

COVID-19 incremental costs

^[5]

4,539

13,209

Assets

5,492,567

$ 5,425,582

Life Sciences

Segment Reporting Information [Line Items]

Revenues

115,658

98,650

232,570

195,435

Segment operating income

46,433

32,315

94,894

65,354

Applied Sterilization Technologies

Segment Reporting Information [Line Items]

Revenues

169,547

152,907

321,909

307,193

Segment operating income

76,835

65,386

140,790

133,421

Assets

2,850,052

2,720,205

Corporate

Segment Reporting Information [Line Items]

Segment operating income

(58,155)

(50,956)

(110,522)

(106,353)

Segment operating income

Segment Reporting Information [Line Items]

Revenues

756,132

736,840

1,425,064

1,433,643

Segment operating income

169,909

149,780

312,315

285,972

Healthcare [Member] [Member]

Segment Reporting Information [Line Items]

Revenues

470,927

485,283

870,585

931,015

Segment operating income

104,796

103,035

187,153

193,550

Healthcare and Life Sciences [Member]

Segment Reporting Information [Line Items]

Assets

2,642,515

$ 2,705,377

Other foreign locations [Member]

Segment Reporting Information [Line Items]

Revenues

189,593

183,568

352,444

354,111

UNITED STATES

Segment Reporting Information [Line Items]

Revenues

549,449

538,101

1,041,157

1,049,253

UNITED KINGDOM

Segment Reporting Information [Line Items]

Revenues

17,090

15,171

31,463

30,279

Consumable revenues [Member] | Life Sciences

Segment Reporting Information [Line Items]

Revenues

55,793

42,540

114,635

86,569

Consumable revenues [Member] | Healthcare [Member] [Member]

Segment Reporting Information [Line Items]

Revenues

122,797

116,033

206,551

232,115

Sales Revenue, Services, Net [Member] | Life Sciences

Segment Reporting Information [Line Items]

Revenues

30,624

29,648

58,264

55,635

Sales Revenue, Services, Net [Member] | Healthcare [Member] [Member]

Segment Reporting Information [Line Items]

Revenues

216,457

216,619

404,279

425,414

Capital equipment revenues [Member] | Life Sciences

Segment Reporting Information [Line Items]

Revenues

29,241

26,462

59,671

53,231

Capital equipment revenues [Member] | Healthcare [Member] [Member]

Segment Reporting Information [Line Items]

Revenues

$ 131,673

$ 152,631

$ 259,755

$ 273,486

[1]	For more information regarding our restructuring efforts refer to Note 2 titled, "Restructuring".
[2]	For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
[3]	Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
[4]	Costs incurred in connection with the Redomiciliation.
[5]	COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.

Shares and Preferred Shares Ordinary Shares (Details)	3 Months Ended		6 Months Ended
Shares and Preferred Shares Ordinary Shares (Details)	Sep. 30, 2020 $ / shares shares	Sep. 30, 2019 shares	Sep. 30, 2020 $ / shares shares	Sep. 30, 2019 shares	Sep. 30, 2020 EUR (€) shares	Mar. 31, 2020 $ / shares
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding - basic	85,170,000	84,795,000	85,065,000	84,716,000
Dilutive effect of share equivalents	674,000	900,000	695,000	914,000
Weighted average shares outstanding and share equivalents - diluted	85,844,000	85,695,000	85,760,000	85,630,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Authorized					50,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001		$ 0.001			$ 0.001
Preferred Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001		$ 0.001
Deferred Ordinary Shares					25,000
Employee share option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of share options that are antidilutive	503,000	341,000	416,000	231,000
Euro Member Countries, Euro
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Par Value (Euros) of Deferred Ordinary Shares \| €					€ 1.00

Shares and Preferred Shares Preferred Shares (Details)	Sep. 30, 2020 $ / shares
Class of Stock [Line Items]
Preferred shares, par value	$ 0.001

Repurchases of Shares (Details) - USD ($) $ in Thousands	6 Months Ended
Repurchases of Shares (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 30, 2019	Jul. 30, 2019	May 07, 2019
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized	$ 333,932		$ 300,000	$ 78,979
Shares repurchased during period, number	35,000	205,059
Aggregate value of shares repurchased pursuant to authorization	$ 5,047	$ 30,000
Shares obtained in connection with share based compensation award programs	76,286	73,914
Payments for shares obtained in connection with share based compensation programs	$ 9,386	$ 7,955

Share-Based Compensation Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	3,568,985
Weighted-average assumptions used for options granted:
Risk-free interest rate	0.46%	2.26%
Expected life of options	6 years	6 years 2 months 12 days
Exptected dividend yield of stock	0.96%	1.22%
Expected volatility of stock	23.04%	20.27%
Estimated forfeiture rate	2.78%	2.77%
Summary of share option activity:
Outstanding at March 31, 2017	1,796,126
Granted	288,936
Exercised	(292,199)
Forfeited	(32,002)
Outstanding at June 30, 2017	1,760,861
Exercisable at June 30, 2017	988,477
Weighted average exercise price:
Outstanding at March 31, 2017	$ 91.29
Granted	181.33
Exercised	71.96
Forfeited	121.80
Outstanding at June 30, 2017	108.72
Exercisable at June 30, 2017	$ 80.98
Average Remaining Contractual Term, Outstanding at June 30, 2017	7 years
Aggregate Intrinsic Value, Outstanding at June 30, 2017	$ 120,484
Average Remaining Contractual Term, Exercisable at June 30, 2017	5 years 8 months 12 days
Aggregate Intrinsic Value, Exercisable at June 30, 2017	$ 94,113
Non-vested stock options outstanding expected to vest	749,747
Ordinary shares, closing price	$ 176.19
Total intrinsic value of stock options exercised	$ 25,244	$ 35,886
Net cash proceeds from the exercise of stock options	$ 20,600	$ 22,371
Weighted average grant date fair value of stock option grants, per share	$ 27.66	$ 23.52
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 57,787
Weighted Average Period For Total Compensation Expense Not Yet Recognized	2 years 3 months 18 days
Stock Appreciation Rights (SARs) [Member]
Weighted average exercise price:
FairValueOfOutstandingStockAppreciationRights	$ 448	$ 587
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	575,830
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 98.07
Number of Restricted Shares, Granted	137,385
Weighted-Average Grant Date Fair Value, Granted	$ 164.45
Number of Restricted Shares, Vested	(156,390)
Weighted-Average Grant Date Fair Value, Vested	$ 84.64
Number of Restricted Shares, Canceled	(15,430)
Weighted-Average Grant Date Fair Value, Canceled	$ 102.07
Number of Restricted Shares, Non-vested at End of Period	541,395
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 119.72
Fair Value, Share-based Payment Awards, Other than Options	$ 14,604
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	30,894
Number of Restricted Shares, Granted	14,124
Number of Restricted Shares, Vested	(16,150)
Number of Restricted Shares, Canceled	0
Number of Restricted Shares, Non-vested at End of Period	28,868

Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2020 USD ($)
Product Warranty Liability [Line Items]
Balance, March 31, 2017	$ 7,381
Warranties issued during the period	4,866
Settlement made during the period	(5,296)
Balance, June 30, 2017	$ 6,951

Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands, € in Millions, $ in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) lb	Sep. 30, 2019 USD ($)	Sep. 30, 2020 EUR (€)	Sep. 30, 2020 MXN ($)	Sep. 30, 2020 CAD ($)	Mar. 31, 2020 USD ($)
Derivative [Line Items]
Non-derivative Net Investment Hedge	$ 48,753		$ 48,753
Prepaid & Other
Derivative [Line Items]
Asset derivatives	538		538					$ 124
Liability derivatives	0		0					0
Accrued expenses and other
Derivative [Line Items]
Asset derivatives	0		0					0
Liability derivatives	609		609					$ 912
Foreign currency forward contracts \| Selling, general, and administrative expense
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	(223)	$ 299	$ (80)	$ 705
Commodity swap contracts
Derivative [Line Items]
Derivative, notional amount, weight \| lb			357,600
Commodity swap contracts \| Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	$ (386)	$ (796)	$ (751)	$ (669)
Mexican peso \| Foreign currency forward contracts
Derivative [Line Items]
Liability derivatives						$ 69.9
Canadian dollar \| Foreign currency forward contracts
Derivative [Line Items]
Liability derivatives							$ 4.5
euro \| Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount \| €					€ 8.0

Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Foreign currency forward contracts \| Selling, general, and administrative expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ 223	$ (299)	$ 80	$ (705)
Commodity swap contracts \| Cost of revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ 386	$ 796	$ 751	$ 669

Fair Value Measurements Fair Value Hierarchy (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Mar. 31, 2020

Reported Value Measurement [Member]

Assets:

Cash and cash equivalents

$ 312,028

$ 319,581

Forward and swap contracts

^[1]

538

124

Equity Securities, FV-NI

^[2]

9,868

9,624

Investments

2,654

2,507

Liabilities:

Forward and swap contracts

^[1]

609

912

Deferred compensation plans

^[2]

1,662

1,475

Contingent consideration obligations

16,364

15,988

Debt Instrument, Fair Value Disclosure

^[3]

1,020,554

1,150,521

Debt and Equity Securities, Gain (Loss)

384

$ 721

$ 2,479

Investment Owned, at Cost

4,955

Contingent consideration obligations

16,364

15,988

Level 1

Assets:

Cash and cash equivalents

312,028

319,581

Forward and swap contracts

Equity Securities, FV-NI

^[2]

9,868

9,624

Investments

2,654

2,507

Liabilities:

Forward and swap contracts

Deferred compensation plans

^[2]

1,662

1,475

Contingent consideration obligations

Debt Instrument, Fair Value Disclosure

Level 2

Assets:

Cash and cash equivalents

Forward and swap contracts

^[1]

538

124

Equity Securities, FV-NI

Investments

Liabilities:

Forward and swap contracts

^[1]

609

912

Deferred compensation plans

Contingent consideration obligations

Debt Instrument, Fair Value Disclosure

^[3]

1,081,626

1,143,978

Level 3

Assets:

Cash and cash equivalents

Forward and swap contracts

Equity Securities, FV-NI

Investments

Liabilities:

Forward and swap contracts

Deferred compensation plans

Contingent consideration obligations

^[4]

16,364

15,988

Debt Instrument, Fair Value Disclosure

$ 0

[1]	The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[2]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the second quarter and first half of fiscal 2021, we recorded losses of $384 and $74, respectively, related to these investments
[3]	We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[4]	Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates

Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($)
$ in Thousands

6 Months Ended

Sep. 30, 2020

Mar. 31, 2020

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Contingent consideration

$ 16,364

$ 15,988

Additions

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Change in contingent consideration

538

Payments

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Change in contingent consideration

(42)

Foreign currency translation adjustment

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Change in contingent consideration

(120)

Fair Value, Inputs, Level 3 [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Contingent consideration

^[1]

16,364

15,988

Fair value

$ 0

[1]

Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates

Fair Value Measurements Available-for-sale securities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Debt Securities, Available-for-sale [Line Items]
Equity Securities, FV-NI, Gain (Loss)	$ (384)	$ (721)	$ (74)	$ (2,479)

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2019

Mar. 31, 2019

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Accumulated Other Comprehensive Income (Loss), Net of Tax

$ (130,613)

$ (225,717)

$ (130,613)

$ (225,717)

$ (208,354)

$ (235,463)

$ (156,844)

$ (159,778)

Other Comprehensive Income (Loss), Net of Tax

78,575

(68,178)

106,518

(64,549)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

(834)

(695)

^[1]

(1,668)

(1,390)

Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent

(77,741)

68,873

(104,850)

65,939

Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax

(7,833)

(5,215)

(7,833)

(5,215)

(7,323)

(6,813)

(4,709)

(4,204)

Other Comprehensive Income (Loss), Net of Tax

324

189

648

379

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[2]

(834)

(695)

(1,668)

(1,390)

Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent

510

506

1,020

1,011

Accumulated Foreign Currency Adjustment Attributable to Parent [Member]

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax

(122,780)

(220,502)

(122,780)

(220,502)

$ (201,031)

$ (228,650)

$ (152,135)

$ (155,574)

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax

78,251

(68,367)

105,870

(64,928)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[1]

Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent

$ (78,251)

$ 68,367

$ (105,870)

$ 64,928

[1]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
[2]	The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

Loans Receivable (Details) € in Thousands, $ in Thousands	12 Months Ended
Loans Receivable (Details) € in Thousands, $ in Thousands	Mar. 31, 2017 EUR (€)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 EUR (€)	Mar. 31, 2020 USD ($)	Mar. 31, 2020 EUR (€)	Oct. 31, 2019 EUR (€)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investments		$ 4,955
Line of Credit Provide		11,000
Loan Agreement Max Borrowing Amount Dutch Linen Sale \| €	€ 15,000
Financing Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Net		9,864		$ 7,084
Loans Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest Rate Period	15 years
Other Receivables		$ 8,545	€ 7,300	$ 8,072	€ 7,300	€ 7,300
Years 1-4, 4% Int Rate [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate on loan receivable	4.00%					4.00%
Years 5-6,8% Int Rate [Member] [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate on loan receivable						8.00%
Loan Rate 4% [Member] [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate on loan receivable		4.00%	4.00%
Years 5-15, 12% Int Rate [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate on loan receivable	12.00%

Restructuring (Details)
$ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2020

USD ($)

Sep. 30, 2019

USD ($)

Sep. 30, 2020

USD ($)

plan

Sep. 30, 2019

USD ($)

Restructuring and Related Cost, Expected Number of Positions Eliminated | plan

200

Restructuring Charges

^[1]

$ (76)

$ 636

$ 90

$ 2,943

Restructuring Costs

(76)

(274)

1,115

Restructuring Costs LTD Since Plan Inception

43,941

Restructuring Costs

(76)

(274)

1,115

Restructuring Charges

^[1]

$ (76)

$ 636

$ 90

$ 2,943

Restructuring and Related Activities Disclosure [Text Block]

Restructuring

Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency.

Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,941 related to these restructuring actions, of which $31,750 was recorded as restructuring expenses and $12,191 was recorded in cost of revenues, with a total of $34,116, $7,474 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,683. Additional restructuring expenses related to this plan are not expected to be material to our results of operations.

Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at September 30, 2020 and March 31, 2020 are not material.

For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.

Operating Income (Loss) [Member]

Restructuring Costs

$ 31,750

Restructuring Costs

31,750

Cost of Sales [Member]

Restructuring Costs

12,191

Restructuring Costs

12,191

Corporate, Non-Segment [Member]

Restructuring Costs

1,683

Restructuring Costs

1,683

Applied Sterilization Technologies [Member]

Restructuring Costs

7,474

Restructuring Costs

7,474

Life Science Member [Member]

668

668

34,116

$ 34,116

[1]	For more information regarding our restructuring efforts refer to Note 2 titled, "Restructuring".

Subsequent Events (Details) $ in Thousands	6 Months Ended
Subsequent Events (Details) $ in Thousands	Sep. 30, 2020 USD ($)
Subsequent Events [Abstract]
Subsequent Event, Date	Oct. 02, 2020
Subsequent Event - Business Acquisition Purchase Price of Entity	$ 850,000
Subsequent Event - Purchase Price of Entity Net of Tax Benefits	810,000
Subsequent Event - Unsecured Term Loan Credit Facility	$ 550,000
Subsequent Events	Subsequent Events On October 2, 2020, we entered into a purchase agreement to acquire all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a portfolio company of Water Street Healthcare Partners, LLC and is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical is expected to be integrated into our Healthcare segment. We anticipate that the acquisition will be completed before December 31, 2020. The purchase price is $850,000 in cash, or approximately $810,000 net of tax benefits, and is subject to customary adjustments. We are not assuming any pre-existing debt, and intend to fund the purchase through a combination of debt and cash on hand. On October 2, 2020, we entered into a financing commitment with several lenders providing for the establishment of a new senior unsecured three year term loan credit facility to be effective upon closing of the acquisition in the amount of $550,000 to partially fund the acquisition. As a result of limited access to the information required to prepare the initial accounting, we are unable to provide the amounts that will be recognized at the acquisition date for the major classes of assets acquired and liabilities assumed, pre-existing contingencies, goodwill or other intangible assets at the time of this Form 10-Q filing.
Subsequent Event [Line Items]
Subsequent Event - Business Acquisition Purchase Price of Entity	$ 850,000
Subsequent Event - Purchase Price of Entity Net of Tax Benefits	$ 810,000
Long-term Debt, Term	3 years
Subsequent Event - Unsecured Term Loan Credit Facility	$ 550,000
Subsequent Event, Date	Oct. 02, 2020